PubMed Health⌕ Search

Biomedical subjects

A Pfleiderer

Publications and source records attributed to A Pfleiderer.

At least 37 records · Page 2Linked to original sources
PubMed1989

The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer. EGF receptors and factors in gynecological carcinomas.

In this study we investigated the presence of epidermal growth factor receptors (EGF-R) and the tissue levels of EGF-like factors (EGF-F) in ovarian, endometrial, cervical and breast carcinomas. EGF-R were found in 33/40 (83%) cervical, 15/26 (58%) endometrial, 64/141 (45%) ovarian, and 19/59 (33%) breast carcinomas. The highest number of EGF-R binding sites was detected in cervical carcinomas followed by endometrial, breast and ovarian carcinomas. The tissue concentrations of EGF-like factors, were investigated in extracts of 63 ovarian, 25 breast, 12 cervical, 14 endometrial carcinomas and in 21 biopsies of nonmalignant tissue such as myometrium and ovaries. The extracts of nonmalignant tissues had a mean EGF-F level of 1.5 +/- 0.7 ng/mg with a concentration range from 0 to 4 ng/mg. The mean EGF-F levels of malignant tissues were: ovarian carcinomas 4.2 +/- 1.5 ng/mg (range 0-15 ng), endometrial carcinomas 4.5 +/- 1.7 ng/mg (range 0-12 ng), cervical carcinomas 4.15 +/- 1.1 ng/mg (range 0-8) and breast carcinomas 3.16 +/- 1.1 ng/mg (range 0-10 ng). About 30% ovarian, endometrial and cervical carcinomas and 16% breast carcinomas, respectively, had enhanced EGF levels from 5 ng/mg to 15 ng/mg compared to nonmalignant tissues. The EGF-F of tissue extracts consists of EGF and transforming growth factor TGF alpha) as shown by the results of EGF and TGF alpha radioimmunoassays. It is assumed that in some tumors the EGF-F tissue levels influence the number of biochemically detectable EGF binding sites.

Binding Sites↗
PubMed1989

Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF-R) and EGF-like factors (EGF-F).

We have studied the concentration of epidermal growth factor receptors (EGF-R) in 115 different malignant ovarian tumors (101 ovarian carcinomas) and EGF-like factors (EGF-F) in tissue extracts of 63 different ovarian carcinomas and 20 non-malignant tissues. 36% of ovarian carcinomas are EGF-R positive. The calculated mean EGF-F level of 4.2 +/- 1.5 ng mg-1 (range: 0-15 ng mg-1) in ovarian carcinomas is significantly enhanced compared to 1.5 +/- 0.7 ng mg-1 (range: 0-4 ng mg-1) of non-malignant tissue extracts. The correlation between EGF-R positive as well as negative ovarian carcinomas and the results of a primary chemotherapy of advanced ovarian carcinomas (n = 92) revealed a significantly higher remission rate of EGF-R positive tumors (66%) compared to EGF-R negative cases (23%). 84% of tumors with progressive disease were EGF-R negative. The mean EGF-F levels were calculated for prognostic subgroups of ovarian carcinomas. Increased EGF-F levels are significantly associated with progressive disease compared to all patients or the remission group. 15/16 cases with EGF-F levels greater than 5 ng mg-1 showed progressive disease. The overall survival time of patients with tumor tissue EGF-F levels greater than 3.5 ng mg-1 was worse than that of patients with low EGF-F levels. Multivariate analysis showed that the EGF-F level was, after grading, the second most important factor for predicting overall survival.

Epidermal Growth Factor↗
PubMed1989

Flow-cytometric prognostic factors for the survival of patients with ovarian carcinoma: a 5-year follow-up study.

Fresh surgical specimens of 37 patients with previously untreated ovarian carcinomas were investigated by means of flow cytometry. The aim of the study was to look for cellular prognostic factors, in addition to the well-known clinical prognostic factors, of survival time for these patients. All patients underwent chemotherapy after surgery, and all patients had a minimum of 5 years of follow-up. Patients with diploid or near-diploid tumors (DNA index less than or equal to 1.25) survived significantly longer than those with aneuploid tumors (DNA index greater than 1.25, P = 0.02). Patients whose tumors showed a high proportion of SG2M phase cells (greater than 17%) or a low proportion of G0/G1 phase cells had shorter survival times than those with tumors with a low proportion of SG2M phase tumor cells (less than or equal to 17%, P = 0.01) or a high proportion of G0/G1 phase tumor cells. There is no significant relationship between cytometric data and stage. Different surgical procedures, cytostatic treatment, histological tumor type, and differentiation had no significant effects on the survival time of patients in this study. Thus, the data from this study demonstrate strong cytometric prognostic factors of the survival of patients with ovarian carcinomas.

Adult↗
PubMed1989

Prognosis of the adenocarcinoma of the cervix uteri: a comparative study.

The different prognoses for patients with adenocarcinomas and squamous cell carcinomas of the cervix uteri were proved by matched-pair analysis. One hundred forty-four patients with adenocarcinoma treated in 1964-1985 were compared in a ratio of 1:2 with 268 patients with squamous cell carcinoma comparable in age, stage, and treatment modality. In both groups 45% of patients were in stage I, 38% in stage II, 15% in stage III, and 2% in stage IV. Five- and 10-year survivals of patients with adenocarcinoma were significantly lower than for those with squamous cell carcinoma (53% resp. 42% vs 68% vs 58%, P = 0.006). In an analyses of patients' prognosis according to clinical stage there was no significant difference between both groups in stages III and IV treated exclusively by radiotherapy. No significant differences were found in stage I and II patients treated by radical surgery. However, the most significant difference in prognosis was seen in stage I and II patients treated by radiotherapy. Five-year survival was 58.6% in stage I adenocarcinomas compared with 85.0% in squamous cell carcinomas. It can be concluded from these results that a discussion of the problem of FIGO staging is more necessary than a discussion of the different radiosensitivities of these two histological types. Surgical treatment must have the same priority as radical surgery or staging laparotomy for exact histologic staging in adenocarcinomas of the cervix uteri.

Adenocarcinoma↗
PubMed1989

Tumour reduction and chemotherapy in ovarian cancer.

The strategy of treatment for ovarian cancer has changed within recent years. Today, our aim is to resect as much tumour tissue as possible, and to treat the rapidly growing tumour residual by efficient chemotherapy. The real effect of this therapy has been assessed from a group of patients at the university hospital of Freiburg. We analysed all patients with Stage III disease who had been admitted to our hospital during a 15-year period. In the period 1984-1986, tumour tissue was reduced to a so-called optimal tumour size in 51% of all cases--in contrast to the results obtained in the period 1972-1974, when this was done in only 14% of cases. In 75% of cases, compared with 28% formerly, a partial resection of tumour was performed. It is remarkable that, at present, 37% of our patients with Stage III disease are older than 70 years. The size of the tumour residual is directly correlated with patients' survival. There is an apparent improvement in the fact that cases which are only histological cases III are more frequent today. Women subjected to more extensive surgery have less frequent postoperative mortality when compared with those who do not have extensive tumour resection. As is well known, the response of residual tumour to chemotherapy is of great importance for survival. At present, chemotherapy is started in almost 90% of cases, but it is subsequently carried through in only 77%. The differences between histologically complete remissions and primary progression are more marked than are the differences between macroscopically negative tumour residual and no tumour resection. The success of a more active form of operation must be seen in the fact that in cases where there is a small residual tumour the rate of complete remission is higher. A stronger reduction of tumour, with subsequent chemotherapy, leads to a slight improvement in the rate of cure.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

[SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].

The TA-4 antigen obtained from squamous cell carcinoma of the uterine cervix has a subunit, the SCC antigen, which can be measured in serum with a polyclonal antibody in a radioimmunoassay. SCC values less than or equal to 1.5 ng/ml were found in 96% of 48 clinically healthy women. This concentration was then set as the cut off value. Of the 122 patients with untreated squamous cell carcinoma of the cervix, 76% had SCC concentrations above 1.5 ng/ml. The CEA was raised in 50% of the cases. In stages III and IV, 89% of the SCC values was raised and 65% of the CEA. Among the 50 patients with recurrent or progressive cervical carcinoma elevated levels of SCC were found in 78% and raised CEA concentrations in 52%. Only in 25% of the cases were both tumour markers raised at the same time. Complete remission was clinically established in 48 patients with cervical carcinoma who had had increased SCC values prior to therapy. The SCC values were in the normal range in 71% of the patients, the CEA values were normal in 81%. The increase in SCC concentration often preceded the tumour recurrence by months. Up to 70% of the patients with vaginal or vulvar carcinoma had elevated SCC levels. SCC proved to be a valuable tumour marker for the follow up of cervical, vaginal, and vulvar cancer.

Adenocarcinoma↗
PubMed1988

Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas.

Ninety-eight different malignant adnexal tumors were analyzed for the presence of epidermal growth factor (EGF)-specific binding sites and binding parameters were calculated by Scatchard plot analysis [G. Scatchard, Ann. N.Y. Acad. Sci. 51, 660-672 (1949)]. Thirty-four biopsies were EGF receptor (EGF-R) positive with dissociation constants (KD) of 0.5-12 X 10(-9) M and binding capacities (Bmax) of 2-250 fmol/mg. One tumor had a KD of 60 X 10(-9) M and a Bmax of 1660 fmol/mg. The correlation of EGF-R status with clinical parameters showed no significant differences in primary, metastatic, or recurrent tumors, histological subtype, tumor differentiation, and tumor residual after primary surgery. As an inverse correlation, EGF-R-positive tumors are 39% and EGF-R-negative tumors 60% progesterone receptor positive. A response to chemotherapy was noticed in 50% of EGF-R-positive ovarian carcinomas with a mean survival time of patients of 28 months. The response rate of EGF-R negative ovarian carcinomas was 12% with a mean survival time of 16 months. Regarding the treatment schedule the major differences were noticed in the cis-platinum plus cyclophosphamide treatment group. These results suggest that the biology of ovarian carcinomas is influenced by growth factors and their receptors, which can be used as prognostic factors.

Adnexa Uteri↗
PubMed1988

[Detection of human papilloma virus (HPV) DNA in vulvar cancers].

Using Southern Blot hybridization 18 invasive malignant tumours of the vulva and 2 intraepithelial vulvar neoplasias were tested for the prevalence of HPV-DNA. In 6 of 11 primary squamous carcinomas, including one carcinoma of the Bartholinic gland, HPV 16 could be identified. Contrarily, in all seven recurrent vulvar tumours examined, including 5 squamous carcinomas, 1 fibrosarcoma and 1 zylindroma, no HPV-DNA was found. No correlation existed between HPV status of the tumours and grade of differentiation or keratinization, or the tumour-stage and lymph-node status. In one tumour-invaded lymph-node HPV 16 was detected as in the corresponding primary tumour. 12 samples from tumour free abdominal skin considered as corresponding normal tissue specimens were negative for HPV-DNA. A correlation between clinical course of the disease and HPV status of the primary tumours was not observed.

Biopsy↗
PubMed1988

[Self-inflicted necroses (mastitis factitia) as an unusual course of non-puerperal mastitis].

The present paper reports of a long lasting necrotising mastitis which, regarding the psychiatric aspect of the patient as well, has to be interpreted as artefactual mastitis. The uncommon localisation, the unusual history and histology as well as the hardly accessible personality may be indicative of a self inflicted injury with subsequent inflammation. Additional to the local therapy, these patients need a psychological guidance, avoiding direct confrontation with the suspected pathogenesis.

Abscess↗
PubMed1988

[CO2 laser therapy and typing of human papilloma virus in follow-up studies of cervix intraepithelial neoplasms].

In 104 woman patients with cervical intraepithelial neoplasia (CIN) I-III who had been treated between 1981 and May 1986 in the dysplasia consulting-room of the Department of Gynecology by means of conisation effected by laser, we checked on therapeutic success via cytology and colposcopy as well as by human papilloma virus (HPV) typing. In 90.3% of the cases 1.25 laser treatments sufficed for healing of the lesion. Relapses occurred mainly in severe intraepithelial neoplasias with identified HPV 16/18. Incidence of HPV was reduced from 56% before therapy to 13.3% after therapy. This shows that laser therapy can be regarded as an effective treatment of the causes of the disease even in CIN associated with HPV. The markedly increased relapse rate in CIN III (24%) makes a reliable follow-up mandatory especially in such cases.

Cervix Uteri↗